Cyclacel Q1 net loss $5.8M; non-dilutive $4.7M tax credit bolsters cash into Q1 2024

Bio Green Med Solution, Inc.

2023-Q1 EPS reported -$0.47

Net loss $5.8M in Q1 2023 vs $4.1M year ago; cash $11.4M plus $4.7M R&D tax credit received.
R&D expenses $5.7M, up 14% YoY, with fadraciclib costs $4.1M and plogosertib $1.4M.
Expects Phase 1/2 data for oral fadraciclib and plogosertib in 2023; Phase 2 PoC enrollment ready.
Cash runway estimated into Q1 2024; royalty income declined $1.1M YoY.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bio Green Med Solution, Inc. reported first quarter ended March 31, 2023 results: net income Net loss for the three months ended March 31, 2023, was $5.8 million.

Period: first quarter ended March 31, 2023
Net income: Net loss for the three months ended March 31, 2023, was $5.8 million
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2023, was $5.8 million, compared to $4.1 million for the same period in 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Bio Green Med Solution, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-059117

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.